BIONET Group:

Leading the Way in the Biotechnology and Pharmaceutical Era

BIONET Corp. has a long-standing reputation in the field of regenerative medicine, with approvals from Taiwan’s Ministry of Health and Welfare for their adipose-derived MSCs(Mesenchymal Stem Cells) to treat degenerative arthritis, knee cartilage defects and chronic wounds, and CIK cells for cancer treatment.

In regards to exosomes, BIONET Corp. has long been studying the applications of exosomes and had successfully launched related commercial skin care products in 2015.

In 2022, BIONET Therapeutics was established to further accelerate the development of cell therapy products and exosome-related diagnostics and therapies, providing a wider range of services.

Our goal is to actively expand collaborations with domestic and international partners to accelerate the pace of discovery and bring innovative treatments to patients around the world.